Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025#Bicara #Therapeutics #Demonstrates #Deep #Durable #Responses #Ficerafusp #Alfa #Pembrolizumab #HPVNegative #HNSCC #ASCO